VINCRISTINE, BCNU, DOXORUBICIN, AND PREDNISONE (VBAP) COMBINATION IN THE TREATMENT OF RELAPSING OR RESISTANT MULTIPLE-MYELOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
- 1 January 1982
- journal article
- research article
- Vol. 66 (6) , 1267-1271
Abstract
A total of 151 patients with myeloma who had relapsed with or were resistant to melphalan and/or cyclophosphamide (Cytoxan) with prednisone received vincristine, carmustine (BCNU), doxorubicin (Adriamycin) and prednisone (VBAP) at 21-day intervals; 39 patients (25%) responded. Of the 123 patients with relapsing myeloma, 37 (30%) responded. Only 2 (7%) of the 28 patients with resistant myeloma responded. The regimen was well-tolerated in patients who had not had prior extensive irradiation. Thrombocytopenia was the most frequent form of toxicity. Survival was significantly longer in those patients responding to VBAP (median, 78 wk) than in those not responding (median, 33 wk) (P = 0.002). VBAP is a safe, effective regimen for patients with myeloma who relapse with alkylating agents.This publication has 6 references indexed in Scilit:
- MULTIPLE-MYELOMA RESISTANT TO MELPHALAN - TREATMENT WITH CYCLOPHOSPHAMIDE, PREDNISONE, AND BCNU1979
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myelomaCancer, 1978
- UNMAINTAINED REMISSIONS IN MULTIPLE-MYELOMA1978
- PHASE-II STUDY OF ADRIAMYCIN AND BLEOMYCIN IN PATIENTS WITH MULTIPLE-MYELOMA1978
- Combination therapy for multiple myelomaCancer, 1977
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976